Restless Leg Syndrome

Primary mechanism—Dopaminergic dysfunction

• Reduced dopaminergic activity in the brain and spinal cord is the leading pathophysiological hypothesis
• Decreased expression of dopamine receptors (particularly D2 and D3) in putamen and substantia nigra
• Impaired dopamine transporter (DAT) function, resulting in reduced dopamine reuptake and synaptic availability
• Evening and nighttime exacerbation correlates with diurnal dopamine level fluctuations
• Paradoxical dopamine agonist augmentation phenomenon suggests complex receptor-level dysfunction

Iron metabolism defect

• Brain iron deficiency occurs independently of systemic iron stores; low cerebrospinal fluid (CSF) ferritin and elevated transferrin despite normal serum iron levels
• Reduced expression of divalent metal transporter 1 (DMT1) and ferroportin impairs iron transport across the blood-brain barrier
• Iron is critical for tyrosine hydroxylase function and dopamine synthesis; deficiency impairs dopaminergic neurotransmission
• Mitochondrial iron accumulation paradoxically coexists with cytoplasmic iron deficiency
• Serum ferritin levels <50 ng/mL correlate with symptom severity

Sensory pathway dysregulation

• Abnormal A-delta and C-fiber sensory signal transmission from lower extremities
• Spinal cord dorsal horn hyperexcitability with increased glutamate and substance P levels
• Altered endogenous opioid system function; reduced enkephalin and endorphin availability
• Magnesium and calcium channel dysfunction contributing to neuronal hyperexcitability
• Brain imaging shows altered activation in motor cortex, putamen, and anterior cingulate during symptom provocation

Primary (idiopathic) RLS

• Accounts for 80% of cases; strong genetic component with autosomal dominant inheritance pattern
• Identified susceptibility loci: BTBD9, MEIS1, MAP2K5, SKOR1, and TOX3 genes
• Family history present in 40-60% of patients with primary RLS
• Earlier age of symptom onset (typically 20s-40s) compared to secondary RLS

Secondary RLS causes

• Iron deficiency anemia: Most common modifiable cause; serum ferritin <50 ng/mL highly associated
• Chronic kidney disease: Present in 20-50% of dialysis patients; uremic toxins may contribute
• Pregnancy: Occurs in 10-15% of pregnant women, typically resolving postpartum; related to iron depletion and hormonal changes
• Peripheral neuropathy: Diabetic, uremic, and idiopathic small-fiber neuropathies
• Parkinson disease: Can occur concurrently; dopaminergic medications may worsen RLS
• Multiple myeloma and other malignancies: Paraneoplastic syndrome or direct neural infiltration
• Rheumatologic diseases: Systemic lupus erythematosus, rheumatoid arthritis, fibromyalgia
• Sleep apnea: May coexist; unclear if causative relationship

Exacerbating factors and risk factors

• Medications: Selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, antipsychotics, antihistamines, metoclopramide
• Caffeine, nicotine, and alcohol: Acute exacerbation of symptoms
• Advanced age: Progressive worsening of symptoms over decades
• Female gender: 1.5-2× higher prevalence; exacerbation during menses and pregnancy
• Sleep deprivation and stress: Significant symptom amplification
• Sedentary lifestyle: Physical immobility worsens urge to move

Cardinal symptoms (diagnostic criteria)

• Irresistible urge to move the legs, often accompanied by uncomfortable sensations
• Sensations described as creeping, crawling, tingling, burning, aching, or throbbing—typically bilateral and symmetrical
• Symptoms primarily affect shins and feet but may involve thighs or even arms
• Symptoms worse during periods of rest or inactivity; temporarily relieved by movement (walking, stretching, massage)
• Evening and nighttime predominance; symptoms typically begin 30 minutes to 3 hours after lying down or sitting
• Duration typically ≥30 minutes and severe enough to impair sleep or functioning

Associated sleep disturbances

• Periodic leg movements during sleep (PLMS): Involuntary, stereotyped leg kicks occurring in clusters at 20-40 second intervals throughout the night
• Sleep fragmentation with frequent arousals (20-50+ arousals per hour in moderate-severe disease)
• Sleep onset insomnia and sleep maintenance insomnia
• Daytime somnolence, fatigue, and impaired cognitive function

Physical examination findings

• Normal neurological examination in primary RLS (no objective sensory or motor deficits)
• Periodic limb movements observable during wakefulness in some patients (voluntary or involuntary)
• Lower extremity edema or skin changes if secondary to chronic venous insufficiency
• Signs of underlying secondary etiology (e.g., pallor in anemia, signs of uremia, neuropathic examination findings)
• Absence of tremor, rigidity, or other Parkinsonian features (helps distinguish from Parkinson disease)

Psychological and social impact

• Significant distress and impaired quality of life comparable to other chronic conditions
• Anxiety regarding inability to sit through movies, flights, or workplace meetings
• Depression related to chronic sleep disruption
• Marital discord from bed partner sleep disruption by periodic leg movements

Clinical diagnostic criteria (ICSD-3)

1. 1.An urge to move the legs, usually accompanied by uncomfortable sensations (paresthesias)
2. 2.Urge/sensations begin or worsen during periods of rest or inactivity (lying, sitting ≥10 minutes)
3. 3.Urge/sensations partially or totally relieved by movement (walking, stretching, jiggling)
4. 4.Urge/sensations worse in the evening or night compared to daytime (circadian pattern)
5. 5.Occurrence ≥3 nights per week and causing significant distress or sleep disruption

Severity rating scale

• International Restless Legs Syndrome Severity Scale (IRLS): 10-item validated questionnaire; scores 0-10 (mild), 11-20 (moderate), 21-30 (severe), 31-40 (very severe)
• Assesses frequency, intensity, and impact on sleep and daytime functioning

Laboratory testing

• Serum ferritin and iron studies: Essential initial test; ferritin <50 ng/mL suggests iron deficiency warranting supplementation regardless of hemoglobin
• Complete blood count (CBC): Assess for anemia; may reveal microcytosis
• Comprehensive metabolic panel: Screen for renal dysfunction (elevated creatinine, BUN)
• Thyroid-stimulating hormone (TSH): Rule out hypothyroidism, which can exacerbate RLS
• Fasting glucose or hemoglobin A1c: Screen for diabetes (associated with neuropathy-related RLS)
• CSF ferritin measurement: Research tool showing reduced levels even with normal serum ferritin; not routinely available

Polysomnography (sleep study)

• Indicated when diagnosis unclear or to assess periodic leg movement index (PLMI) for severity
• Shows periodic leg movements during sleep (PLMS): EMG bursts 0.5-5 seconds in tibialis anterior muscles, occurring ≥15 movements per hour diagnostic
• Demonstrates sleep fragmentation with frequent arousals related to leg movements
• Can exclude sleep apnea and other primary sleep disorders
• Suggested Immobilization Test (SIT): Formal sleep lab procedure assessing leg movements during 60-minute period of sitting; highly specific for RLS when positive

Imaging

• MRI brain: Not routinely needed; may be considered if atypical presentation or focal neurological signs present
• Consider if suspecting secondary causes (e.g., spinal cord lesion, demyelination)

Diagnostic approach to secondary RLS

• Screen for all secondary causes in every patient before diagnosing primary RLS
• Particular attention to iron stores (serum ferritin), renal function, and medications
• If secondary cause identified, treat underlying condition as first-line approach

General non-pharmacological measures (first-line foundation)

• Sleep hygiene optimization: Regular sleep schedule, cool dark environment, avoidance of stimulants near bedtime
• Lifestyle modifications: Regular aerobic and resistance exercise (particularly 4-6 hours before bedtime), leg massage, heat application
• Avoid exacerbating factors: Eliminate caffeine, nicotine, and alcohol; review medications for RLS-worsening agents (SSRIs, antipsychotics, antihistamines)
• Cognitive behavioral therapy: Address anxiety and sleep-related cognitions
• Education and reassurance: Many patients benefit from understanding the condition is not harmful

Iron supplementation (when ferritin <50 ng/mL)

• First-line pharmacotherapy in iron-deficient patients, regardless of hemoglobin level
• Oral ferrous sulfate 325 mg daily or ferrous bisglycinate 25-30 mg elemental iron once or twice daily
• Intravenous iron (iron sucrose, ferric carboxymaltose) if oral supplementation ineffective or malabsorption present
• Take on empty stomach with vitamin C for enhanced absorption; separate from other medications by ≥2 hours
• Effect takes 8-12 weeks to manifest; check ferritin response at 3 months
• Target ferritin level ≥50-100 ng/mL; some experts recommend 150 ng/mL for optimal symptom control

Dopamine agonists (most effective pharmacological class)

• Pramipexole: Initial dose 0.125 mg nightly, titrate every 3-7 days; typical maintenance 0.25-0.75 mg nightly (max 4.5 mg/day)
• Ropinirole: Initial dose 0.25 mg nightly, titrate; typical maintenance 1-4 mg nightly (max 6 mg/day)
• Rotigotine patch: Transdermal delivery 1-3 mg/24 hours; advantages include steady-state levels reducing augmentation risk
• Mechanism: Stimulate D2/D3 dopamine receptors, increasing dopaminergic neurotransmission in basal ganglia and spinal cord
• Efficacy: 60-70% of patients achieve ≥50% symptom improvement
• Start low, go slow: Begin with lowest dose at night; gradual titration improves tolerability
• Augmentation risk: Long-term levodopa use (>5 years) causes "augmentation" (earlier symptom onset, spread to upper body, shorter duration of action) in 50% of patients; lower risk with dopamine agonists, especially rotigotine patch

Levodopa/carbidopa

• Rapid onset of action (30-60 minutes); useful for intermittent RLS
• Dosing: 100/25 mg to 250/25 mg once or twice nightly
• Disadvantage: High augmentation rate (up to 80% at 5 years); reserve for intermittent symptoms or add-on therapy only
• Earlier disease onset and faster symptom progression if used as monotherapy long-term

Alpha-2-delta ligands (secondary agents)

• Gabapentin: Initial 300 mg nightly, titrate to 1800-2400 mg/day in divided doses; effective especially in neuropathic RLS
• Pregabalin: Initial 150 mg nightly, titrate to 300-600 mg/day; FDA-approved for RLS
• Gabapentin enacarbil: Extended-release formulation; 600 mg once daily at 5 PM; FDA-approved, optimal bioavailability
• Mechanism: Block calcium channels, reduce excitatory neurotransmitter release, reduce sensory hyperexcitability
• Advantages: Non-dopaminergic mechanism reduces augmentation risk; also improve sleep quality; benefit patients with comorbid anxiety or neuropathy
• Use when: First-line dopamine agonist ineffective, poorly tolerated, or augmentation develops

Benzodiazepines (symptomatic relief, not disease-modifying)

• Clonazepam 0.25-0.5 mg nightly: Improves sleep but does not treat underlying RLS; risk of dependence
• Reserved for short-term use or adjunctive therapy when dopamine agonists inadequate
• Can mask underlying sleep apnea; contraindicated if sleep apnea present

Opioid medications (third-line, special situations)

• Tramadol: 50 mg nightly to BID, can titrate to 300 mg/day; reduces symptoms in refractory cases
• Low-dose opioids: Codeine, morphine, methadone in severe refractory RLS unresponsive to dopamine agonists
• Use with caution: Risk of dependence, tolerance, adverse effects; reserve for severe disease significantly impacting quality of life after other options exhausted
• Monitor carefully; obtain patient agreement regarding opioid use

Combination therapy

• Two-drug regimen often superior to monotherapy for moderate-severe disease
• Dopamine agonist + gabapentin/pregabalin: Synergistic benefit, different mechanisms reduce augmentation
• Dopamine agonist + low-dose levodopa for PRN use on heavy symptom days
• When augmentation occurs: Switch to alternative dopamine agonist or gabapentinoid; do not simply escalate dose

Treatment algorithm by severity

• Non-pharmacological measures + lifestyle modification
• Levodopa 100-250 mg for PRN use on symptomatic nights
• Iron supplementation if ferritin <50 ng/mL

• Iron repletion if indicated
• Dopamine agonist (pramipexole 0.25-0.5 mg or ropinirole 0.5-2 mg nightly)
• OR gabapentin enacarbil 600 mg nightly if dopamine agonist contraindicated
• Add-on levodopa PRN for breakthrough symptoms

• Dopamine agonist at higher doses (pramipexole up to 0.75-1 mg, ropinirole up to 4-6 mg)
• Add gabapentin/pregabalin if inadequate response (typical final dose 1800-2400 mg gabapentin or 300-600 mg pregabalin)
• Consider rotigotine patch for steady-state delivery if augmentation concerns
• Low-dose tramadol or opioids if above regimen ineffective

Monitoring during treatment

• Assess symptom response at 4-8 weeks using IRLS scale
• Monitor for augmentation: Earlier symptom onset, spread to arms/trunk, reduced duration of medication action
• If augmentation develops: Consider switch to non-augmenting agent (gabapentin/pregabalin) or rotigotine patch; attempt dopamine agonist dose reduction
• Periodic recheck of serum ferritin every 6-12 months in iron-supplemented patients
• Screen for medication-induced RLS worsening (SSRIs, antipsychotics) and deprescribe if possible
• Assess for development of sleep apnea (often coexists)

Augmentation (dopaminergic therapy-related)

• Definition: Progressive worsening of RLS despite stable or increasing medication dose, characterized by earlier symptom onset

• The four-word stem: urge to move + worse at Rest + relieved by Movement + Evening/night predominance. If all four appear with a normal neurologic exam, the diagnosis is RLS and no confirmatory test is needed — ICSD-3 (AASM) criteria are purely clinical.
• Single best next step in almost every vignette: check a serum ferritin with iron studies. Ferritin is an acute-phase reactant, so a "normal" value can hide brain iron deficiency; treat when ferritin is below roughly 50 ng/mL (or transferrin saturation is low) even if hemoglobin is normal. Iron is the only truly disease-modifying therapy.
• The association examiners love: secondary RLS from iron deficiency, pregnancy (third trimester, resolves postpartum), and end-stage renal disease on dialysis. Dialysis-associated RLS improves after renal transplant — a classic single-best-answer.
• Drug-provoked RLS: dopamine antagonists (metoclopramide, antipsychotics), sedating antihistamines (diphenhydramine, often hidden in an OTC sleep aid), and most antidepressants — especially mirtazapine. Deprescribing the offender precedes adding a new drug. Bupropion, being dopaminergic, is the antidepressant least likely to worsen symptoms.
• Distractor to avoid — PLMS is not RLS. Periodic limb movements of sleep occur in most RLS patients but are common and asymptomatic in older adults; polysomnography is not required to diagnose RLS and is ordered mainly to exclude comorbid sleep apnea.
• Mimics: nocturnal leg cramps are painful, palpable, focal contractions without an urge to move; akathisia is generalized inner restlessness from antipsychotics without the evening circadian pattern or relief with movement; peripheral neuropathy burns constantly and is not relieved by walking.
• Augmentation — earlier symptom onset, spread to arms/trunk, shorter drug effect — is the tested complication of dopaminergic therapy (highest with levodopa). The wrong answer is increase the dose; correct management is to reassess iron, then transition toward an alpha-2-delta ligand. AASM guidance has moved away from routine long-term dopamine agonist use for this reason.
• Impulse control disorders (gambling, hypersexuality, compulsive shopping) from pramipexole/ropinirole are a favorite pharmacology hook.